Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Heparin - Troikaa Pharmaceuticals

Drug Profile

Heparin - Troikaa Pharmaceuticals

Alternative Names: Heparin QPS - Troikaa; Heparin sodium - Troikaa; Heparin sodium topical solution 1000 IU/ml - Triokaa; Phlebotroy QPS

Latest Information Update: 25 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Troikaa Pharmaceuticals
  • Class Anti-infectives; Anti-inflammatories; Antithrombotics; Bronchodilators; Heparins; Mucolytics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Thrombosis

Most Recent Events

  • 25 Jun 2018 Troikaa Pharmaceuticals plans a phase II/III trial for Phlebitis in India (CTRI/2018/05/013701)
  • 02 May 2017 Troikaa Pharmaceuticals initiates a phase III trial for Thrombosis (Prevention) in India (CTRI2017-03-008263)
  • 30 Mar 2017 Launched for Thrombosis (Prevention) in India prior to March 2017 (Topical)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top